Keymed Biosciences (HKSE:02162) Accounts Payable & Accrued Expense : HK$219.3 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Accounts Payable & Accrued Expense?

Keymed Biosciences's quarterly accounts payable & accrued expense increased from Dec. 2023 (HK$204.3 Mil) to Jun. 2024 (HK$215.0 Mil) and increased from Jun. 2024 (HK$215.0 Mil) to Dec. 2024 (HK$219.3 Mil).

Keymed Biosciences's annual accounts payable & accrued expense increased from Dec. 2022 (HK$118.1 Mil) to Dec. 2023 (HK$204.3 Mil) and increased from Dec. 2023 (HK$204.3 Mil) to Dec. 2024 (HK$219.3 Mil).

Keymed Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Keymed Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Accounts Payable & Accrued Expense Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

71.86

58.06

118.14

204.29

219.31

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial						118.14	131.76	204.29	215.04	219.31

Keymed Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Keymed Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences Headlines

No Headlines